Targeting EGFR through monoclonal antibodies has shown positive outcomes, particularly in patients with recurrent or metastatic head and neck squamous cell carcinoma when other treatments have proven ineffective [13]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.